All In Biotech

Drug Trial Radar · NCT00389870

Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)]

Last checked: Nov 19, 2026Latest source record: Jun 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,198

Actual

Start

Dec 2006

Primary completion

Not stated

Sponsor

Lead sponsor
University of LeedsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the drug. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Panitumumab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether irinotecan is more effective when given with or without panitumumab or cyclosporine in treating colorectal cancer. PURPOSE: This randomized phase III trial is studying irinotecan to compare how well it works when given with or without panitumumab or cyclosporine in treating patients with advanced or metastatic colorectal cancer that did not respond to fluorouracil.

Conditions

  • Colorectal Cancer

Interventions

  • panitumumabBiological

  • cyclosporineDrug

  • irinotecan hydrochlorideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients treated with irinotecan hydrochloride (Ir) alone vs Ir and cyclosporine (IrC) who are progression-free at 12 weeks
  2. Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Bournemouth Hospital

    Bournemouth, England, United Kingdom

  • Sussex Cancer Centre at Royal Sussex County Hospital

    Brighton, England, United Kingdom

  • Bristol Haematology and Oncology Centre

    Bristol, England, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, England, United Kingdom

  • Gloucestershire Oncology Centre at Cheltenham General Hospital

    Cheltenham, England, United Kingdom

  • Eastbourne District General Hospital

    Eastbourne, England, United Kingdom

  • St. Luke's Cancer Centre at Royal Surrey County Hospital

    Guildford, England, United Kingdom

  • Huddersfield Royal Infirmary

    Huddersfield, West Yorks, England, United Kingdom

  • Hinchingbrooke Hospital

    Huntingdon, England, United Kingdom

  • Airedale General Hospital

    Keighley, England, United Kingdom

  • Cookridge Hospital

    Leeds, England, United Kingdom

  • Royal Liverpool University Hospital

    Liverpool, England, United Kingdom

  • UCL Cancer Institute

    London, England, United Kingdom

  • Queen Elizabeth Hospital - Woolwich

    London, England, United Kingdom

  • St. Mary's Hospital

    London, England, United Kingdom

  • Mid Kent Oncology Centre at Maidstone Hospital

    Maidstone, England, United Kingdom

  • Clatterbridge Centre for Oncology

    Merseyside, England, United Kingdom

  • James Cook University Hospital

    Middlesbrough, England, United Kingdom

  • Mount Vernon Cancer Centre at Mount Vernon Hospital

    Northwood, England, United Kingdom

  • Peterborough Hospitals Trust

    Peterborough, England, United Kingdom

  • Dorset Cancer Centre

    Poole Dorset, England, United Kingdom

  • Portsmouth Oncology Centre at Saint Mary's Hospital

    Portsmouth Hants, England, United Kingdom

  • Cancer Research Centre at Weston Park Hospital

    Sheffield, England, United Kingdom

  • South Tyneside District Hospital

    South Shields, England, United Kingdom

  • Royal Marsden - Surrey

    Sutton, England, United Kingdom

  • Great Western Hospital

    Swindon, England, United Kingdom

  • Worthing Hospital

    Worthing, England, United Kingdom

  • Yeovil District Hospital

    Yeovil, England, United Kingdom

  • Edinburgh Cancer Centre at Western General Hospital

    Edinburgh, Scotland, United Kingdom

  • Ysbyty Gwynedd

    Bangor, Wales, United Kingdom

  • Velindre Cancer Center at Velindre Hospital

    Cardiff, Wales, United Kingdom

  • Glan Clwyd Hospital

    Rhyl, Denbighshire, Wales, United Kingdom

  • South West Wales Cancer Institute

    Swansea, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.